Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

CG Oncology (CGON) Equity Average (2023 - 2025)

CG Oncology's Equity Average history spans 3 years, with the latest figure at $720.1 million for Q4 2025.

  • For Q4 2025, Equity Average rose 13.39% year-over-year to $720.1 million; the TTM value through Dec 2025 reached $720.1 million, up 13.39%, while the annual FY2025 figure was $743.0 million, 143.49% up from the prior year.
  • Equity Average reached $720.1 million in Q4 2025 per CGON's latest filing, up from $679.0 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $720.1 million in Q4 2025 to a low of -$115.3 million in Q4 2023.
  • Average Equity Average over 3 years is $405.4 million, with a median of $560.6 million recorded in 2024.
  • Peak YoY movement for Equity Average: skyrocketed 711.04% in 2024, then grew 13.39% in 2025.
  • A 3-year view of Equity Average shows it stood at -$115.3 million in 2023, then soared by 650.6% to $635.1 million in 2024, then increased by 13.39% to $720.1 million in 2025.
  • Per Business Quant, the three most recent readings for CGON's Equity Average are $720.1 million (Q4 2025), $679.0 million (Q3 2025), and $687.6 million (Q2 2025).